FDA Initiates Class II Recall of Eugia US LLC's Progesterone Injection Due to Glass Particulate Contamination
Eugia US LLC faces a Class II FDA recall for 17,136 vials of Progesterone Injection, USP, due to glass particulate contamination. This voluntary action, recall number D-0624-2024, impacts nationwide US distribution. Procurement and regulatory teams must assess immediate supply disruptions for this critical hormone therapy and review quality assurance protocols for sterile injectables, particularly those sourced internationally.
FDA Initiates Class II Recall for Eugia US LLC's Progesterone Injection Due to Particulate Matter
Eugia US LLC, based in East Windsor, NJ, has initiated a Class II voluntary recall for 17,136 vials of its Progesterone Injection, USP, 500 mg per 10 mL (50mg/mL), 10 mL Multiple-Dose Vial. This critical hormone therapy, identified by NDC 55150-306-10 and Lot #: CPR230029A, was recalled following a complaint of a glass particle found within a vial. The recall, designated D-0624-2024, commenced on July 26, 2024, with the FDA classifying it on August 1, 2024. A Class II classification signifies that the product's use may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, the presence of foreign particulate matter in a sterile injectable poses a direct physical hazard, including potential for emboli, phlebitis, or allergic reactions, depending on the particle's nature and size. This event necessitates immediate action from procurement and regulatory teams. Procurement directors must promptly identify and quarantine all affected stock, assessing the immediate impact on their inventory and patient supply. Regulatory affairs heads must understand the implications of this quality failure, particularly concerning sterile product manufacturing standards, which are among the most stringent in the pharmaceutical industry. This incident underscores the critical need for robust incoming material inspection and in-process quality controls, especially for parenteral products.
Eugia US LLC's Supply Chain Footprint and International Sourcing Risks
Eugia US LLC, operating from East Windsor, NJ 08520, serves as the recalling firm and the US distributor for this Progesterone Injection. Crucially, the product is explicitly stated as "Mfd. in India for: Eugia US LLC." This highlights a multi-national supply chain model, where manufacturing occurs overseas, and distribution is managed domestically. The recall of 17,136 vials signifies Eugia US LLC's substantial role in supplying Progesterone Injection to the US market, making this quality incident particularly impactful. The reliance on international manufacturing sites introduces additional layers of supply chain complexity and regulatory oversight challenges. For supply chain VPs, this event underscores the imperative of comprehensive vendor qualification and ongoing oversight of contract manufacturing organizations (CMOs), especially those located in different regulatory jurisdictions. The incident demands a thorough review of quality agreements and audit programs for all internationally sourced sterile injectables. Regulatory affairs heads must ensure that their firm's import processes and quality systems are robust enough to detect and prevent such manufacturing defects from reaching the US market, mitigating both patient risk and potential regulatory enforcement actions against the US distributor.
Critical Supply Chain Vulnerabilities for Progesterone in the US Healthcare System
The nationwide distribution of 17,136 affected vials of Progesterone Injection, USP, creates significant supply chain vulnerabilities across the United States. Progesterone is a vital hormone used in a range of therapeutic applications, including supporting early pregnancy, managing menstrual disorders, and as part of hormone replacement therapy. Disruptions to its supply can have immediate and serious consequences for patient treatment plans and healthcare provider operations. The presence of particulate matter in an injectable drug, even if classified as Class II, can erode patient and clinician confidence in the drug supply, potentially leading to treatment delays or the need for alternative, possibly less optimal, therapies. Procurement directors must immediately assess the depth of their inventory and the potential for localized or national shortages. This requires rapid communication with pharmacies, hospitals, and group purchasing organizations to understand the scope of impact and coordinate mitigation strategies. Business development executives should evaluate the market dynamics, identifying potential gaps and opportunities for alternative products or formulations. Supply chain VPs must activate robust contingency plans, including exploring expedited qualification processes for new suppliers or alternative dosage forms, to ensure continuity of care and minimize operational disruptions across the healthcare network.
Strategic Diversification: Mitigating Progesterone Supply Risks
The current recall, coupled with a parallel FDA Class II recall in June 2026 involving Essential Wellness Pharma's Progesterone Injection due to sterility assurance issues, highlights systemic quality control challenges within the broader Progesterone injectable market. While the knowledge graph does not identify specific alternative suppliers, this recurring pattern emphasizes the critical need for pharmaceutical companies to diversify their sourcing strategies for essential molecules like Progesterone. Relying on a single manufacturer or a limited number of suppliers, especially for sterile injectables, significantly amplifies supply chain risk. Procurement teams must proactively engage in identifying and qualifying multiple alternative manufacturers for Progesterone Injection. This strategic diversification should prioritize suppliers with demonstrably strong quality management systems, a clear history of regulatory compliance, and ideally, manufacturing sites across different geographic regions to buffer against regional disruptions. Qualification timelines for new sterile injectable suppliers can be extensive, often spanning 12-24 months, necessitating immediate action. Regulatory affairs departments must streamline the review and approval processes for new supplier onboarding, ensuring that all quality and regulatory requirements are met without compromising speed to market for critical therapies.
Heightened Regulatory Scrutiny and Eugia US LLC's Compliance Pathway
This voluntary, firm-initiated recall (D-0624-2024) places Eugia US LLC under heightened FDA scrutiny, particularly concerning the quality control processes at its contract manufacturing site in India. While the available information does not detail prior enforcement actions against Eugia US LLC, the discovery of particulate matter in a sterile injectable is a serious quality system failure that demands a comprehensive investigation. The "Ongoing" status of the recall indicates that the FDA will closely monitor Eugia US LLC's effectiveness checks, product disposition, and, critically, its root cause analysis and proposed corrective and preventive actions (CAPA). Regulatory affairs heads at Eugia US LLC must prepare for potential FDA follow-up inspections, which could extend to the manufacturing facility in India. Failure to adequately address the root cause and implement effective CAPAs could escalate to an FDA Form 483, a Warning Letter, or even an Import Alert, severely impacting the company's ability to supply the US market. For other industry players, this event serves as a critical reminder to reinforce internal quality audits, conduct rigorous due diligence on third-party manufacturers, and maintain transparent communication channels with regulatory bodies to preempt similar recalls and safeguard market access and brand reputation.